DOW JONES NEWSWIRES C.R. Bard's (BCR) second-quarter profit jumped 11% as the maker of vascular, urology and oncology medical products posted higher sales across the board. Earlier this month, C.R. Bard closed on its $213 million acquisition of SenoRx, a deal that is expected to cut 2010 earnings by 3 cents to 6 cents a share. The company said it believes the combination will offer a broader range of breast care products to customers. Meanwhile, C.R. Bard saw demand slump last year as hospitals and individuals cut back on their products, although results have rebounded in 2010. It posted a second-quarter profit of $124.7 million, or $1.29 a share, up from $112.4 million, or $1.11 a share, a year earlier. Excluding acquisition-related charges and other items, earnings rose to $1.39 from $1.23. Revenue climbed 7.9% to $673.9 million, and rose 7% on a constant-currency basis. In April, C.R. Bard projected earnings of $1.34 to $1.38 on constant-currency sales growth of 6% to 8%. Vascular sales, the company's largest segment by revenue in the latest quarter, grew 11%, while urology sales were up 2.9% and oncology sales increased 6.6%. Sales in the company's surgical specialties climbed 16%. Earlier Thursday, Morgan Joseph said it believed the company would begin ramping up its research-and-development efforts more aggressively, and those costs grew 8.2% during the quarter. The firm added it expected new product launches to help C.R. Bard hit its top-line numbers. Shares closed up at $77.35 on Thursday and were inactive after-hours. -By John Kell, Dow Jones Newswires; 212-416-2480; john.kell@dowjones.com
